Results 81 to 90 of about 16,883 (239)

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, EarlyView.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

Outcomes of real‐world initiation of long‐acting injectable cabotegravir and rilpivirine (LA‐I CAB + RPV) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations

HIV Medicine, Volume 27, Issue 1, Page 42-57, January 2026.
Abstract Background When using long‐acting injectable cabotegravir and rilpivirine (CAB + RPV) in individuals with viraemia, beyond small cohorts, little is known about baseline characteristics, virological failure outcomes, resistance emergence, re‐suppression and discontinuation.
Alexa Elias, Chloé Pasin, Melanie Smuk, Amy Paterson, Chloe M. Orkin   +4 more
wiley   +1 more source

Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies [PDF]

, 2023
Alicja Jakimiuk, Agnieszka Piechal, Alicja Wiercińska‐Drapało, Alicja Nowaczyk, Dagmara Mirowska-Guzeł   +4 more
openalex   +1 more source

Metabolic Syndrome and Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy in Northern Tanzania

Journal of the International Association of Providers of AIDS Care
Purpose Chronic systemic inflammation from human immunodeficiency virus (HIV) may cause metabolic abnormalities in lipid metabolism. Additionally, the development of metabolic syndrome has been associated with specific anti-retroviral therapy ...
Tumaini E Mirai, K. Kilonzo, Abid M. Sadiq, I. A. Muhina, N. J. Kyala, Annette A Marandu, Sarah K Gharib, Andrea R Costantine, E. Mkwizu, William P Howlett, E. Shao, G. Nyakunga, Huda F Akrabi, V. Kshettry, V. Maro, Nyasatu G. Chamba, Furaha S. Lyamuya   +16 more
semanticscholar   +1 more source

People living with HIV on modern antiretrovirals do not display a pro‐atherogenic lipid profile and have similar body composition compared to healthy controls

HIV Medicine, Volume 27, Issue 1, Page 86-95, January 2026.
Abstract Objectives Alterations in lipids and apolipoproteins contribute to cardiovascular disease (CVD) and are common in people with HIV. The aim of our study was to compare lipid profiles and body composition between people with and without HIV and to explore whether any associations with HIV could be explained by socio‐demographic, clinical ...
S. Savinelli, A. Heeney, W. Tinago, A. A. Garcia Leon, P. McGettrick, A. G. Cotter, I. Walsh, M. Fitzgibbon, C. A. Sabin, P. W. G. Mallon, E. R. Feeney, on behalf of the HIV UPBEAT study group   +11 more
wiley   +1 more source

An effective stability indicating RP-HPLC method for simultaneous estimation of Dolutegravir and Lamivudine in bulk and their tablet dosage form

Future Journal of Pharmaceutical Sciences, 2020
Background A Simple, sensitive, and specific stability indicating reverse phase HPLC method was developed for simultaneous estimation of Lamivudine and Dolutegravir in bulk and tablet dosage form.
Ramreddy Godela, Sowjanya G
doaj   +1 more source

Exploring the Solubility and Bioavailability of Sodium Salt and Its Free Acid Solid Dispersions of Dolutegravir

Advances in Pharmacological and Pharmaceutical Sciences, 2023
Amorphous salt solid dispersion (ASSD) of Dolutegravir amorphous salt (DSSD) was generated using quench cooling and compared to its Dolutegravir free acid solid dispersion (DFSD) to improve the solubility and bioavailability. Soluplus (SLP) was used as a
Dani Lakshman Yarlagadda, Akshatha M. Nayak, Bheemisetty Brahmam, Krishnamurthy Bhat   +3 more
doaj   +1 more source

Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa

British Journal of Clinical Pharmacology
Dolutegravir increases serum creatinine by inhibiting its renal tubular secretion and elimination. We investigated determinants of early changes in serum creatinine in a southern African cohort starting first‐line dolutegravir‐based antiretroviral ...
Rephaim Mpofu, A. Kawuma, R. Wasmann, Godspower Akpomiemie, N. Chandiwana, Simiso M Sokhela, Michelle A. Moorhouse, W. D. F. Venter, P. Denti, L. Wiesner, Frank A. Post, David W Haas, G. Maartens, P. Sinxadi   +13 more
semanticscholar   +1 more source

Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025

HIV Medicine, Volume 27, Issue 1, Page 18-32, January 2026.
Abstract Background The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. Key Points of the Guidelines Update The structure of the guidelines has been reorganized into two parts: Part I focuses on the management and prevention of HIV and related infections, and Part ...
Juan Ambrosioni, Laura I. Levi, Jasmini Alagaratnam, Abiu Sempere, Andrea Mastrangelo, Paolo Paioni, Cristina Mussini, Catia Marzolini, Susanne Dam Nielsen, Charles Béguelin, Steven Welch, Anna Koval, Luis Mendao, Alasdair Bamford, Alexandra Calmy, Giovanni Guaraldi, Cristiana Oprea, Esteban Martínez, Jürgen K. Rockstroh, The EACS Governing Board   +19 more
wiley   +1 more source

An evaluation of postmarketing reports of hyperglycaemia associated with dolutegravir for treatment of HIV in Eswatini

AIDS Research and Therapy, 2022
Background Dolutegravir (DTG) is an Integrase Strand Transfer Inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV infection.
Alemayehu L. Duga, Sibongile Magongo, Siphesihle Nhlabatsi, Denis O. Ladwar, Linda Härmark, Leàn Rolfes   +5 more
doaj   +1 more source